Mexican Assets Have Worst Day Since 2020 Lockdown: Why Sheinbaum Is Shaking Investor Confidence
Sheinbaum is Mexico's new president; Today, the peso is down 3.9% and ETFs recorded double-digit losses. What happened?
‘Dogecoin Killer’ Shiba Inu Burn Rate Spikes 1,442%, Trader Predicts Price ‘Potentially Doubling Or Even Tripling’
Shiba Inu (CRYPTO: SHIB) witnessed a significant increase in the past 24 hours burn rate, with traders bullish about its upcoming price momentum.
Alcoa Set For Gains As China’s Aluminum Market Surplus Grows, Global Supply Tightens: JPMorgan
JPMorgan's Commodities Research team predicts turbulence in aluminum prices near term due to oversupply, but forecasts a rebound in the longer term.
Why ‘You Should Only Buy Bitcoin’ And All Other Top 20 Cryptos Are ‘Really Jokes,’ According To This Trader
Bitcoin investor Fred Krueger pointed out why “you should only buy Bitcoin (CRYPTO: BTC),” even though there have been
Structure Therapeutics’ Obesity Candidate Is ‘ Very Competitive’ To Eli Lilly’s Orforglipron, Analyst Says
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
Biden To Sign Executive Order To Limit Asylum Seekers Crossing US-Mexico Border: Report
A Biden executive order comes after GOP Senators killed a bipartisan immigration bill earlier this year at the behest of Trump.
GSK’s Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or refractory multiple myeloma compared to bortezomib with PomDex.
Roaring Kitty Reignites Koss Stock: What’s Next For Investors?
Koss Corp stock surge coincides with Roaring Kitty's return on social media. Interest in meme stocks like GME and AMC drives gains despite weak fundamentals. Technical analysis shows bullish trend, but caution advised due to potential pullback.
Why Is German Biotech Affimed Stock Soaring On Monday?
Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab.
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with potential milestones and royalties up to $577 million.